Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 8,500 shares, an increase of 214.8% from the November 30th total of 2,700 shares. Based on an average daily volume of 898,500 shares, the days-to-cover ratio is currently 0.0 days.
Provectus Biopharmaceuticals Stock Up 2.3 %
Provectus Biopharmaceuticals stock traded up $0.00 during trading hours on Thursday, hitting $0.12. The stock had a trading volume of 162,587 shares, compared to its average volume of 255,911. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.22. The stock's fifty day moving average is $0.12 and its two-hundred day moving average is $0.11.
About Provectus Biopharmaceuticals
(
Get Free Report)
Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Provectus Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Provectus Biopharmaceuticals wasn't on the list.
While Provectus Biopharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
